Clinical Trial Search

Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. — 1.75; 2.11 exacerbations per year — p=0.1042

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio

Primary: Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug — 155; 150 milliliters (mL) — p=0.021

Primary: COPD Diagnosis — 39 participants

Primary: Subjects With ≥1 Treatment-emergent Adverse Event — 2; 3; 2; 2 Participants

Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants

Primary: Change in Total Ventilation Volume — 0.154317; -0.13687 Litres

Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001

Primary: Number of Moderate to Severe Exacerbation (Defined as Requiring Treatment With Systemic Corticosteroids and/or Antibiotics in the Community or Hospital or…

Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage

Primary: Total Number of Healthcare Visits — 111; 76; 119; 93 Participants

Primary: Dyspnea Intensity — 8.0; 6.5; 7.75; 5 units on a scale

Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L

Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84

Primary: Percentage of Participants With COPD Who Rate the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrate Correct Use of the Inhaler at the End of…

Primary: Total COPD Exacerbation Rate — 1.00; 0.86; 0.89 Exacerbations per participant year

Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24 — 0.122; 0.056; -0.019 Liters — p=<0.001

Primary: Mean Number of Pharmacy Claims by Participants During the Post-Index Period — 2.960; 0.219; 5.491; 0.573 pharmacy claims

Primary: Change in Percentage Ventilated Defect Percent (VDP) — -0.14 % change in VDP

Primary: Mean Area Under the Concentration Time Curve Over the Dosing Period (AUC[0-tau]) for FP — 376.9; 573.1; 350.5; 559.1 Picogram hours per milliliter (pg*h/mL)

Primary: The Difference Between the Values of Area Under the Response Curve for FEV1 — 203.0; 185.0 mcg*hr/mL

Primary: The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event — 5; 5; 3; 3 Participants

Primary: Change From Baseline in Clinic Trough Forced Expiratory Volume in One Second (FEV1) at the End of Treatment Phase A (Visit 6/Day 29) — 0.047; 0.146; 0.193; 0.175 Liters…

Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 0.99; 1.21; 1.09; 1.17 Exacerbations per year — p=0.0638

Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants

Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1

Primary: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation — 200; 674 participants — p=0.002